Please login to the form below

Not currently logged in
Email:
Password:

Positive opinion for Allergan's NDO treatment

A positive opinion is given from the Irish Medicines Board for BOTOX treatment for neurogenic detrusor overactivity (NDO)

Allergan's BOTOX has received a positive opinion from the Irish Medicines Board, for the use of BOTOX for the management of urinary incontinence in adults with neurogenic detrusor overactivity (NDO).

NDO results from neurogenic bladder, due to stable sub-cervical spinal cord injury (SCI) or multiple sclerosis (MS). NDO results in involuntary contractions of the detrusor muscle within the bladder during its filling stage. This over activity often leads to urinary incontinence.

It has been shown that targeted injections of BOTOX into the bladder muscle can reduce the involuntary contractions and increase bladder capacity, therefore reducing the number of urinary leaks.

Gaining this opinion is considered to be an important step towards securing national licences in the 14 European countries involved in the Mutual Recognition Procedure.

9th August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hive

We're a healthcare communications agency that does things differently. We put patients at the heart of everything we do, while...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics